CAGE Bio earns recognition as the Rising Star by the BioNorthTX at the iC3® Summit 20
Background: Nitin has been actively engaged in pharmaceutical product development in the industry since Feb 1998, when (at Elan Pharmaceuticals), he first started studying interactions between powders and polymer surfaces to improve the efficiencies of pulmonary dry powder inhalation products for asthma and COPD. He moved into formulation and process development thereafter and became fully entrenched in pharmaceutical dosage form development. He has actively contributed to various drug delivery products from new chemical entities to drug delivery applications for known molecules. In 2006, he started working on a transdermal product for post- operative pain at ALZA Corporation. He led the development of the next-generation version of IONSYS, a drug-device combination transdermal product. He believed in the technology and the value of the product, so when the company terminated the program he got together with outside investors and created Incline Therapeutics to get this product approved and to the market. The product eventually succeeded in securing approval in the US and the European Union.
Background: Prof. Mitragotri has made groundbreaking contributions to the field of biological barriers and drug delivery. His research has advanced fundamental understanding of biological barriers and has led to the development of new materials as well as technologies for diagnosis and treatment of various ailments including diabetes, cardiovascular diseases, skin diseases and infectious diseases, among others. Many of his technologies have advanced to human clinical studies and products. At the same time, fundamental understanding developed through his research has advanced the understanding of the biology of barriers in the human body. Currently, he is employed as the Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences. His research is focused on transdermal, oral and targeted drug delivery systems. He is an elected member of the NAE and NAM, and an elected fellow of NAI, AAAS, CRS, BMES, AIMBE, and AAPS.
Background: Ravi is an entrepreneurial biotech executive and technical founder. He is passionate about developing breakthrough first-in-class drug products leveraging novel scientific discoveries. He has a track record in leading companies from inception to exit and developing products from concept through commercialization. His therapeutic areas of interest and experience are oncology, dermatology, ophthalmology, and diabetes. He is an inventor of over 30 patent families and developed the "Microjet Patch-pump" that won the Edison award in the Medical Device game-changer category. He has a wide experience in business plan development, IP portfolio development, in-licensing, key opinion leader (KOL) recruitment and engagement, scientific advisory board (SAB) recruitment, and C-level senior management and board recruitment. He also has a track record in customer engagement, strategic partnership development and management, university in-licensing and collaborations, product portfolio development, go-to-market strategies, in-house and outsourced research and development, CRO/CMO evaluation and management.